Home Data Calendar Blog

ACRS

Tables

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2015-09-30	2014-09-30
Weighted Average Number Of Diluted Shares Outstanding		70.81	70.63	66.87	NA	66.68	65.99	61.43	NA	61.22	53.97	50.34	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Weighted Average Number Of Shares Outstanding Basic		70.81	70.63	66.87	NA	66.68	65.99	61.43	NA	61.22	53.97	50.34	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Earnings Per Share Basic		-0.41	-0.42	-0.42	-0.41	-0.30	-0.31	-0.31	-0.37	-0.35	-0.34	-0.57	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Earnings Per Share Diluted		-0.41	-0.42	-0.42	-0.41	-0.30	-0.31	-0.31	-0.37	-0.35	-0.34	-0.57	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2015-09-30	2014-09-30
Revenue From Contract With Customer Excluding Assessed Tax		9.28	1.87	2.53	7.75	19.02	1.53	1.45	1.50	1.66	1.82	1.78	1.58	1.45	2.05	1.41	1.09	0.98	5.87	5.04	3.67	1.63	3.68	1.12	1.00	0.68	0.00	0.00
Revenues		9.28	1.87	2.53	7.75	19.02	1.53	1.45	1.50	1.66	1.82	1.78	1.58	1.45	2.05	1.41	1.09	0.98	5.87	5.04	3.67	1.63	3.68	1.12	1.00	0.68	0.00	0.00
Cost Of Revenue		0.85	1.04	0.81	0.88	0.92	1.07	1.16	1.15	1.10	1.26	1.20	1.29	1.19	1.39	1.27	1.03	0.83	0.99	1.21	3.51	1.19	1.18	0.97	0.75	0.45	NA	NA
Cost Of Goods And Services Sold		0.85	1.04	0.81	0.88	0.92	1.07	1.16	1.15	1.10	1.26	1.20	1.29	1.19	1.39	1.27	1.03	0.83	2.70	2.78	3.51	1.19	1.18	0.97	0.75	0.45	NA	NA
Costs And Expenses		40.86	33.68	32.45	36.83	39.89	22.52	20.36	24.39	21.95	19.83	30.31	15.14	11.91	13.43	16.91	18.65	23.85	55.66	42.38	25.82	22.46	35.65	32.07	NA	NA	NA	NA
Research And Development Expense		23.88	25.27	22.59	21.07	23.66	18.78	14.31	14.10	13.98	7.90	7.84	8.96	6.87	6.47	9.44	11.56	16.18	17.62	19.92	19.54	15.93	13.98	13.61	13.19	10.86	9.41	2.10
General And Administrative Expense		7.09	8.32	8.79	7.15	5.81	6.08	6.10	6.94	5.98	5.87	4.83	4.90	3.86	5.57	6.20	6.01	6.73	7.99	8.19	6.69	6.57	8.12	6.26	12.50	8.12	1.23	0.56
Operating Income Loss		-31.58	-31.82	-29.92	-29.08	-20.87	-20.99	-18.91	-22.89	-20.30	-18.01	-28.53	-13.56	-10.46	-11.38	-15.51	-17.55	-22.86	-49.79	-37.34	-39.04	-33.45	-31.98	-30.95	-25.44	-18.76	-10.64	-2.66
Allocated Share Based Compensation Expense		5.95	6.52	6.81	4.81	4.19	3.69	2.35	3.85	3.70	3.83	2.67	2.50	1.94	3.31	3.45	3.19	4.02	4.81	4.86	4.96	4.71	5.25	5.14	4.30	3.67	0.16	0.01
Profit Loss		-29.26	-29.57	-28.16	-27.64	-19.95	-20.53	-18.79	-22.80	-21.15	-18.16	-28.75	-13.17	-10.66	-11.60	-15.59	-18.59	-55.32	-49.88	-37.56	-38.55	-32.74	-31.22	-30.23	-22.93	-18.19	NA	NA
Other Comprehensive Income Loss Net Of Tax		-0.02	-0.76	0.54	0.57	-0.14	-0.35	-0.75	-0.22	0.18	-0.04	-0.05	-0.05	-0.06	-0.03	0.11	-0.07	-0.01	0.06	0.02	0.05	0.07	0.14	-0.08	-0.13	0.05	0.00	-0.00
Net Income Loss		-29.26	-29.57	-28.16	-27.64	-19.95	-20.53	-18.79	-22.80	-21.15	-18.16	-28.75	-13.17	-10.66	-11.60	-15.59	-18.59	-55.32	-49.88	-37.56	-38.55	-32.74	-31.22	-30.23	-22.93	-18.19	-10.63	-2.66
Comprehensive Income Net Of Tax		-29.28	-30.33	-27.62	-27.07	-20.09	-20.89	-19.54	-23.02	-20.96	-18.20	-28.80	-13.22	-10.72	-11.63	-15.47	-18.66	-55.33	-49.82	-37.55	-38.50	-32.67	-31.08	-30.31	-23.07	-18.14	-10.63	-2.66

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2015-09-30	2014-09-30
Assets		218.35	235.65	229.71	254.60	267.63	277.98	226.53	251.21	263.49	288.05	161.40	70.78	71.90	85.00	96.81	98.30	160.42	217.24	253.18	275.57	176.18	201.82	220.62	243.51	261.39	42.09	NA
Liabilities		62.02	55.90	52.90	56.98	47.79	42.22	46.33	53.87	46.91	54.23	49.10	33.13	31.14	35.63	38.64	28.39	75.14	80.01	70.93	60.44	29.85	27.62	20.15	18.25	17.13	1.90	NA
Liabilities And Stockholders Equity		218.35	235.65	229.71	254.60	267.63	277.98	226.53	251.21	263.49	288.05	161.40	70.78	71.90	85.00	96.81	98.30	160.42	217.24	253.18	275.57	176.18	201.82	220.62	243.51	261.39	42.09	NA
Stockholders Equity		156.33	179.75	176.81	197.62	219.84	235.75	180.20	197.34	216.58	233.81	112.29	37.65	40.76	49.37	58.17	69.91	85.28	137.23	182.25	215.12	146.33	174.20	200.47	225.26	244.26	-38.12	NA

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2015-09-30	2014-09-30
Assets Current		123.07	132.94	184.36	231.55	256.57	259.35	190.88	205.03	205.78	241.26	134.50	57.49	58.00	70.95	82.71	83.80	145.37	137.89	156.81	179.50	145.52	171.17	192.26	200.22	234.12	39.36	NA
Cash And Cash Equivalents At Carrying Value		39.04	31.15	44.72	45.28	61.65	68.26	36.34	27.35	53.60	113.45	35.27	22.06	23.64	NA	NA	34.19	NA	NA	NA	NA	NA	NA	54.88	20.20	60.05	25.42	18.89
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents		39.04	31.15	44.72	45.28	61.65	68.26	36.34	27.35	53.60	113.45	35.27	22.06	25.40	32.59	53.99	35.94	29.90	31.65	34.20	57.02	26.59	46.03	54.88	20.20	60.05	NA	NA
Accounts Receivable Net Current		0.35	0.43	0.69	0.48	0.60	0.64	0.63	0.62	0.81	0.94	0.82	0.77	0.89	0.78	0.93	0.70	0.67	19.37	15.82	4.86	1.03	2.18	0.53	0.48	NA	NA	NA
Prepaid Expense And Other Assets Current		19.67	12.73	12.87	13.49	7.91	10.11	10.63	12.99	7.09	8.65	5.39	2.59	1.88	2.06	2.78	3.12	2.09	2.82	3.38	5.88	9.17	3.36	4.75	5.88	5.62	0.95	NA
Available For Sale Securities Debt Securities		147.96	179.62	159.68	184.54	186.41	187.56	167.24	198.31	190.01	152.73	107.39	32.07	29.83	35.53	25.01	39.08	61.53	83.86	102.56	110.95	107.68	118.57	132.10	188.65	NA	12.99	NA

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2015-09-30	2014-09-30
Property Plant And Equipment Gross		6.37	6.31	5.72	5.13	5.01	4.98	4.82	4.73	4.38	4.33	4.28	4.28	4.86	4.89	4.55	4.54	5.01	6.71	6.10	5.95	5.75	5.35	2.87	2.64	1.53	0.84	NA
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment		4.60	4.41	4.21	4.04	3.87	3.70	3.54	3.39	3.21	3.04	2.85	2.62	2.94	2.66	2.36	2.07	2.15	2.46	2.07	1.67	1.34	0.98	0.68	0.48	0.33	0.08	NA
Amortization Of Intangible Assets		0.02	0.02	0.02	-55.92	0.02	0.02	0.02	-55.92	0.02	0.02	0.02	NA	NA	NA	NA	NA	NA	1.66	1.66	NA	NA	NA	NA	NA	NA	NA	NA
Property Plant And Equipment Net		1.76	1.90	1.51	1.10	1.15	1.28	1.28	1.33	1.17	1.29	1.42	1.65	1.92	2.23	2.19	2.47	2.85	4.24	4.03	4.28	4.41	4.38	2.19	2.16	1.20	0.76	NA
Intangible Assets Net Excluding Goodwill		6.92	6.93	6.95	6.97	6.99	7.01	7.03	7.05	7.07	7.09	7.11	7.12	7.14	7.16	7.18	7.20	7.22	69.78	71.46	72.95	7.29	7.31	7.33	7.35	NA	NA	NA
Finite Lived Intangible Assets Net		0.29	0.31	0.33	0.34	0.36	0.38	0.40	0.42	0.44	0.46	0.48	0.49	0.51	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Other Assets Noncurrent		2.66	2.89	3.27	2.73	2.92	3.11	3.38	3.55	3.74	3.91	4.01	4.51	4.84	4.65	4.73	4.83	4.97	5.32	2.38	0.33	0.45	0.46	0.34	0.28	0.20	0.02	NA
Available For Sale Debt Securities Amortized Cost Basis		149.09	180.73	160.04	185.44	187.88	188.89	168.21	198.53	190.02	152.74	107.42	32.07	29.83	35.50	24.95	39.07	61.51	83.82	102.55	110.98	107.74	118.69	132.33	188.82	167.84	12.98	NA

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2015-09-30	2014-09-30
Liabilities Current		27.32	22.83	18.26	21.94	19.79	16.22	16.73	22.93	17.84	14.92	14.51	14.87	12.79	17.75	20.60	22.43	38.99	42.75	36.23	27.34	22.28	20.07	13.82	12.76	9.99	1.90	NA
Accounts Payable Current		9.65	11.43	8.19	10.35	7.67	5.70	8.12	9.98	7.56	4.24	7.29	5.25	5.08	5.50	6.95	9.92	17.78	14.16	14.57	14.76	13.73	12.50	8.15	7.82	6.48	0.96	NA
Other Accrued Liabilities Current		0.56	0.75	0.57	0.72	1.74	1.92	1.68	1.73	0.61	1.23	1.16	1.17	0.63	0.66	1.23	1.38	1.08	2.34	2.25	1.03	0.67	0.53	0.54	0.47	0.32	0.01	NA
Accrued Liabilities Current		15.16	8.74	7.26	8.70	9.15	7.57	5.69	10.05	7.41	6.93	3.60	5.91	3.82	9.34	10.37	7.72	6.07	27.60	20.79	12.59	8.54	7.57	5.67	4.94	3.51	0.94	NA
Other Liabilities Current		NA	NA	NA	NA	NA	NA	0.72	0.69	0.67	0.65	0.62	0.60	0.59	0.61	0.62	0.64	0.64	0.99	0.87	0.60	NA	NA	NA	NA	NA	NA	NA

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2015-09-30	2014-09-30
Deferred Income Tax Liabilities Net		0.37	0.37	0.37	0.37	0.37	0.37	0.37	0.37	0.37	0.37	0.37	0.37	0.55	0.55	0.55	0.55	NA	NA	NA	0.55	NA	NA	NA	NA	NA	NA	NA
Other Liabilities Noncurrent		1.83	1.90	1.97	1.57	1.64	1.84	2.04	2.17	2.51	2.92	3.04	3.18	3.13	3.33	3.48	3.74	4.00	5.12	3.30	1.70	1.77	1.75	0.53	0.56	0.38	NA	NA
Operating Lease Liability Noncurrent		1.83	1.90	1.97	1.57	1.62	1.82	2.02	2.20	2.38	2.56	2.73	2.89	3.05	3.25	3.40	3.55	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2015-09-30	2014-09-30
Stockholders Equity		156.33	179.75	176.81	197.62	219.84	235.75	180.20	197.34	216.58	233.81	112.29	37.65	40.76	49.37	58.17	69.91	85.28	137.23	182.25	215.12	146.33	174.20	200.47	225.26	244.26	-38.12	NA
Additional Paid In Capital		926.77	920.90	887.64	880.83	875.98	871.80	795.37	792.97	789.19	785.46	645.73	542.29	532.17	530.06	527.24	523.50	520.21	516.84	512.04	507.37	400.07	395.27	390.46	384.94	380.87	NA	NA
Retained Earnings Accumulated Deficit		-769.30	-740.04	-710.48	-682.32	-654.68	-634.73	-614.20	-595.41	-572.60	-551.46	-533.30	-504.54	-491.37	-480.71	-469.11	-453.53	-434.93	-379.61	-329.74	-292.17	-253.62	-220.88	-189.66	-159.44	-136.50	-38.12	NA
Accumulated Other Comprehensive Income Loss Net Of Tax		-1.13	-1.11	-0.35	-0.90	-1.47	-1.33	-0.97	-0.22	-0.00	-0.18	-0.14	-0.09	-0.04	0.01	0.05	-0.07	-0.00	0.01	-0.05	-0.07	-0.12	-0.19	-0.33	-0.25	-0.11	0.00	NA
Stock Issued During Period Value New Issues		NA	26.71	NA	NA	NA	72.66	NA	NA	NA	134.85	103.35	NA	0.26	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value		5.95	6.52	6.81	NA	4.19	3.69	2.35	NA	3.70	3.83	2.67	NA	1.94	3.31	3.45	NA	3.32	4.81	4.86	4.96	4.71	5.25	5.14	4.30	3.67	NA	NA

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2015-09-30	2014-09-30
Net Cash Provided By Used In Operating Activities		-24.56	-20.65	-26.35	-19.11	-7.82	-19.67	-20.97	-17.07	-10.61	-12.22	-12.23	-8.86	-12.15	-10.82	-6.80	-20.39	-23.36	-21.38	-31.32	-27.25	-29.86	-21.83	-21.87	-18.21	-13.71	NA	NA
Net Cash Provided By Used In Investing Activities		32.53	-19.66	25.80	2.70	1.22	-21.22	29.93	-9.18	-37.67	-45.47	-75.31	-2.31	5.24	-10.49	13.94	56.44	21.67	18.95	8.62	-70.51	10.39	13.29	56.19	-21.57	-39.86	NA	NA
Net Cash Provided By Used In Financing Activities		-0.09	NA	NA	0.04	-0.01	72.81	0.03	-0.00	-11.57	135.87	100.75	7.83	-0.28	-0.10	10.92	-30.01	-0.07	-0.12	-0.12	128.18	0.02	-0.30	0.36	-0.08	80.92	NA	NA

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2015-09-30	2014-09-30
Net Cash Provided By Used In Operating Activities		-24.56	-20.65	-26.35	-19.11	-7.82	-19.67	-20.97	-17.07	-10.61	-12.22	-12.23	-8.86	-12.15	-10.82	-6.80	-20.39	-23.36	-21.38	-31.32	-27.25	-29.86	-21.83	-21.87	-18.21	-13.71	NA	NA
Net Income Loss		-29.26	-29.57	-28.16	-27.64	-19.95	-20.53	-18.79	-22.80	-21.15	-18.16	-28.75	-13.17	-10.66	-11.60	-15.59	-18.59	-55.32	-49.88	-37.56	-38.55	-32.74	-31.22	-30.23	-22.93	-18.19	-10.63	-2.66
Profit Loss		-29.26	-29.57	-28.16	-27.64	-19.95	-20.53	-18.79	-22.80	-21.15	-18.16	-28.75	-13.17	-10.66	-11.60	-15.59	-18.59	-55.32	-49.88	-37.56	-38.55	-32.74	-31.22	-30.23	-22.93	-18.19	NA	NA
Depreciation Depletion And Amortization		0.22	0.22	0.20	0.19	0.19	0.21	0.21	0.20	0.19	0.25	0.29	-0.45	0.59	0.61	0.58	0.32	1.63	2.23	2.23	0.96	0.38	0.32	0.22	0.18	0.12	NA	NA
Increase Decrease In Accounts Receivable		-0.09	-0.26	0.20	-0.11	-0.04	0.00	0.01	-0.19	-0.13	0.12	0.04	-0.12	0.11	-0.16	-4.74	-12.19	-1.51	3.55	10.96	3.83	-1.15	NA	NA	NA	NA	NA	NA
Increase Decrease In Accounts Payable		-2.15	3.23	-2.16	2.69	1.96	-2.42	-1.86	2.36	2.58	-3.13	1.84	0.23	0.58	-1.71	-4.32	-6.21	3.63	-0.39	-0.20	1.03	1.24	4.38	0.32	1.43	-0.03	-0.04	NA
Share Based Compensation		5.95	6.52	6.81	4.81	4.19	3.69	2.35	3.85	3.70	3.83	2.67	2.50	1.94	3.31	3.45	3.18	3.32	4.81	4.86	4.96	4.71	5.25	5.14	4.30	3.67	0.16	NA

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2015-09-30	2014-09-30
Net Cash Provided By Used In Investing Activities		32.53	-19.66	25.80	2.70	1.22	-21.22	29.93	-9.18	-37.67	-45.47	-75.31	-2.31	5.24	-10.49	13.94	56.44	21.67	18.95	8.62	-70.51	10.39	13.29	56.19	-21.57	-39.86	NA	NA
Payments To Acquire Property Plant And Equipment		0.08	0.23	0.55	0.10	0.15	0.19	0.16	0.20	0.06	NA	NA	0.01	0.30	0.02	0.12	0.27	0.82	0.24	0.28	0.15	0.56	0.35	0.30	0.58	0.27	0.13	NA

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2015-09-30	2014-09-30
Net Cash Provided By Used In Financing Activities		-0.09	NA	NA	0.04	-0.01	72.81	0.03	-0.00	-11.57	135.87	100.75	7.83	-0.28	-0.10	10.92	-30.01	-0.07	-0.12	-0.12	128.18	0.02	-0.30	0.36	-0.08	80.92	NA	NA

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2015-09-30	2014-09-30
Revenues		9.28	1.87	2.53	7.75	19.02	1.53	1.45	1.50	1.66	1.82	1.78	1.58	1.45	2.05	1.41	1.09	0.98	5.87	5.04	3.67	1.63	3.68	1.12	1.00	0.68	0.00	0.00
Revenue From Contract With Customer Excluding Assessed Tax		9.28	1.87	2.53	7.75	19.02	1.53	1.45	1.50	1.66	1.82	1.78	1.58	1.45	2.05	1.41	1.09	0.98	5.87	5.04	3.67	1.63	3.68	1.12	1.00	0.68	0.00	0.00
Corporate Non		-4.11	-4.00	-4.01	-3.34	-3.21	-3.18	-2.87	-2.16	-1.92	-1.88	-1.67	-1.83	-1.68	-1.80	-2.22	-3.79	-1.96	-2.92	-3.93	-3.08	-2.11	-1.91	-1.38	-0.99	-0.53	NA	NA
Intersegment Elimination, Contract Research		4.10	4.00	4.00	3.30	3.20	3.20	2.90	2.10	1.90	1.90	1.70	13.20	1.70	1.80	-2.22	-125987.29	-1.96	-2.92	-3.93	-3.08	-2.11	-1.91	-1.38	-0.99	-0.53	NA	NA
Operating, Contract Research		4.82	4.88	NA	NA	4.30	4.40	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Operating, Dermatology Therapeutics		8.58	0.99	NA	NA	17.93	0.31	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Eli Lilly And Company, License And Service, Patent License Agreement		8.30	0.90	1.40	NA	17.60	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Laboratory Research Revenue		0.70	0.88	0.89	0.87	1.09	1.22	1.22	1.27	1.42	1.61	1.53	1.41	1.33	1.85	1.19	1.09	0.98	0.89	1.26	1.27	1.12	1.14	1.12	1.00	0.68	NA	NA
Other Revenue		NA	NA	NA	0.17	0.03	0.31	0.23	0.23	0.24	0.22	0.24	0.17	0.12	0.19	0.22	NA	NA	NA	NA	0.50	0.00	1.00	NA	NA	NA	NA	NA
License And Service		8.58	0.99	1.64	6.72	17.90	0.28	0.20	0.20	0.21	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Royalty, Asset Purchase Agreement Encompassing Worldwide Rights To Oxymetazoline Hydrochloride Cream Plus Intellectual Property		NA	0.10	0.20	0.20	0.30	0.30	0.20	0.20	0.20	0.20	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Contract Research		NA	NA	4.90	4.21	4.30	4.40	4.10	3.43	3.33	3.48	3.20	3.24	3.02	3.66	3.41	4.88	2.94	3.81	5.19	4.36	3.23	3.05	2.50	1.99	1.21	NA	NA
Dermatology Therapeutics		NA	NA	1.64	6.89	17.93	0.31	0.23	0.23	0.24	0.22	0.24	0.17	0.12	0.19	0.22	NA	NA	4.98	3.78	2.40	0.51	2.53	NA	NA	NA	NA	NA

Plots across concepts

Line plots across dimensions of each concept